Professional Documents
Culture Documents
My project as Claris was concerned with finding out the potential of Injectable molecule
which Claris wanted to introduce in its generic Injectable segment. I worked under the
marketing department where in at the onset I was given a thorough orientation of the
organization, its unique business model where in individual entrepreneurship and corporate
governance go hand in hand, some of their well established products, their work culture and
rules and regulations were informed to me.
During the course of my project I had an encouraging practical experience and a chance to
learn the practical aspect of the pharmaceutical industry and the corporate world on the
whole.
Putting my experiences in to words, “Business school is about theory while Business is all
about action.”
1
OBJECTIVES
To find out the opportunity for new injectable drugs which Company do not have and for
which,
There is high future potential in mid to long term and currently less
competitors.
Acceptability is high
To find out new or expected strength for the existing injectable drugs
as well as new drugs.
Competitor scenario
2
INTERODUCTION
Pharmaceutical industry
Pharmaceutical Industry in India is one of the largest and most advanced among the
developing countries. It provides employment to millions and ensures that essential drugs at
affordable prices are available to the vast population of India. Indian Pharmaceutical Industry
has attained wide ranging capabilities in the complex field of drug manufacture and
technology. From simple pain killers to sophisticated antibiotics and complex cardiac
compounds, almost every type of drug is now made indigenously.
Indian Pharma Industry is playing a key role in promoting and sustaining development in the
vital field of medicines. Around 70% of the country's demand for bulk drugs, drug
intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and vaccines
is met by Indian pharmaceutical industry. A number of Indian pharmaceutical companies
adhere to highest quality standards and are approved by regulatory authorities in USA and
UK.
Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units
and is very top heavy. The leading 250 pharmaceutical companies control 70% of the market
with market leader holding nearly 7% of the market share. There are also 5 Central Public
Sector Units that manufacture drugs. These units produce complete range of pharmaceuticals,
which include medicines ready for consumption by patients and about 350 bulk drugs, i.e.,
chemicals having therapeutic value and used for production of pharmaceutical formulations.
India is largely self-sufficient in case of formulations. More than 85% of the formulations
produced in the country are sold in the domestic market. Some life saving, new generation
under-patent formulations are imported, by MNCs, which they market in India. Over 60% of
India's bulk drug production is exported. The balance is sold locally to other formulators.
Pharmaceutical Industry in India has been de-licensed and industrial licensing for most of the
drugs and pharmaceutical products has been done away with. Manufacturers are now free to
produce any drug duly approved by the Drug Control Authority. Indian pharmaceutical
industry got a major boost with the signing of General Agreement on Tariffs and Trade in
January 2005 with which India began recognizing global patents. After recognizing the
3
global patent regime the Indian Pharma market became a sought after destination for foreign
players.
India holds the lion's share of the world's contract research business as activity in the Pharma
market continues to explode in this region. Over 15 prominent contract research
organizations (CROs) are now operating in India attracted by her ability to offer efficient
R&D on a low-cost basis. Thirty five per cent of business is in the field of new drug
discovery and the rest 65 per cent of business is in the clinical trials arena. India offers a huge
cost advantage in the clinical trials domain compared to Western countries. The cost of hiring
a chemist in India is one-fifth of the cost of hiring a chemist in the West.
The future of Indian pharmaceutical sector looks extremely positive. Indian Pharma
companies are vying for the branded generic drug space to register their global presence.
Several Indian pharmaceutical companies have acquired companies in the US and Europe
and many others are raising funds to do so. For example, Ranbaxy acquired Romania's
Terapia, Ethimed NV of Belgium and GSK's generic business Allen SpA in Italy. Dr Reddy's
acquired German generic drug maker Betapharm. Companies like Glenmark Pharma, Lupin,
Aurobindo and Jubilant Organosys are on the lookout for lucrative acquisitions.
(Source:www.worldpharmanews.com)
4
Injectable Drug Market in India
In India , the injectable market has shown significant growth with large potential for more.
The moving annual total in the domestic market for injectables was Rs 5,631.10 crores for
the year-ended-December-2008.
Injectable antibiotics market in particular has witnessed strong growth, the injectable
antibiotics market in India has shown robust growth in the last 4-5 years mainly because of
the introduction of high-end antibiotic brands at higher prices and the subsequent
proliferation of generic versions of many of the leading high-end antibiotic brands.
The domestic injectable antibiotics market is worth $425 million and has been growing at a
CAGR of 21 per cent in the last three years. The domestic market is likely to slow down a bit
and the expected CAGR in the next 5 years is likely to be 16 per cent taking the estimated
market value of injectable to $900 million.
The generic injectables segment that most Indian companies focus on is getting a boost from
government-sponsored healthcare programmes and private insurers. Injectables using small
molecules represent 25% of the market and are estimated to be at $35 billion of world
market, growing at 11%. Most generic injectables use small molecules which comprise 65%
of sales and are focused on oncology and cardiovascular. Monoclonal antibodies and
bioengineered vaccine injectables are expected to grow faster than the market.
(Source:www.pharmaworld.com)
5
Non-prescription drugs
They may be sold “over the counter” since they are judged to be safe for use without
medical supervision.
Prescription drugs
They are considered to be unsafe for use except under medical supervision, therefore ,they
are dispensed only on a physician’s prescription.
GENERIC DRUGS
A generic drug is a drug which is produced and distributed without patent protection. The
generic drug may still have a patent on the formulation but not on the active ingredient.
A generic must contain the same active ingredients as the original formulation. According to
the U.S. Food and Drug Administration (FDA), generic drugs are identical or bioequivalent
to the brand name counterpart with respect to pharmacokinetic and pharmacodynamic
properties. By extension, therefore, generics are identical in dose, strength, route of
administration, safety, efficacy, and intended use.
In most cases, generic products are available once the patent protections afforded to the
original developer have expired. When generic products become available, the market
competition often leads to substantially lower prices for both the original brand name product
and the-generic-forms.
BRANDED DRUGS
A Branded Drug has a trade name and is drug manufactured by a well established
pharmaceutical company, protected by a patent. It cannot be produced or sold by any other
company. A brand name will be simpler than the generic name.
(Source: Elements of Pharmacology
book)
6
WHAT IS INJECTABLE DRUG?
An Injection (often referred to as a "shot") is an infusion method of putting liquid into the
body, usually with a hollow needle and a syringe which is pierced through the skin to a
sufficient depth for the material to be forced into the body. An injection follows a Parenteral
route of administration, that is, administered other than through the digestive tract
Administration involving a needle or syringe occurs with several drug routes. These routes
are referred to as parentaral. Care must be taken to maintain asepsis with all injections and
injection sites. Intramuscular medications are injected into the muscle. All intramuscular
injections involve the practice of land marking, or identifying anatomical markers that
indicate the correct injection site and avoid damage to bone or nerves. Subcutaneous
injections are administered under the skin. Insulin is a common medication that is usually
given subcutaneously. Intradermal medications are used much less frequently than
subcutaneous or intramuscular injections. They are injected into the skin. Intravenous
medications are given through an intravenous line into the vein. These medications may be
mixed with a large amount of solution that is being infused, given in a small solution through
a port in the intravenous tubing (bolus), or attached in smaller infusion containers to the
larger infusion.
In all cases of administration with a needle or syringe, rotation of injection sites is required to
prevent damage to tissue. It is also important that the size of the needle is selected based on
the thickness of the medication to be given and the depth of the injection, while maximizing
the patients level of comfort during insertion. Needle sticks with contaminated needles are a
hazard to both health professional and patient. Care is taken to dispose of needles and
syringes rapidly in impervious containers. Protective systems that sheath the needle after use
are commonly used to prevent inadvertent needle sticks. Injectable or Intravenous (IV)
therapy is very common practice in hospitals; up to 80% of Hospitalized patients receive IV
therapy at some point during their stay in the hospital. Fluids, medications, blood and blood
products and nutrition can all be given by the IV Route which can be either peripheral or
central. IV fluids are administered to restore Hemodynamic stability and to restore fluid and
electrolyte balance. Hence, they are potentially life-saving in many situations.
(Source: www.pharmafocussia.com)
7
TYPE OF INJECTIONAL ROUTE
Intracerebral (into the cerebrum) direct injection into the brain. Used in experimental
research of chemicals and as a treatment for malignancies of the brain.
Intracardiac (into the heart), e.g. adrenaline during cardiopulmonary resuscitation (no
longer commonly performed)
Subcutaneous (under the skin), e.g. insulin, a slang term for this method of
administration is skin popping (usually done with recreational drugs)
Intraosseous infusion (into the bone marrow) is, in effect, an indirect intravenous
access because the bone marrow drains directly into the venous system. This route is
occasionally used for drugs and fluids in emergency medicine and pediatrics when
intravenous access is difficult.
Intradermal, (into the skin itself) is used for skin testing some allergens, and also for
mantoux test for Tuberculosis
Intrathecal (into the spinal canal) is most commonly used for spinal anesthesia and
chemotherapy
8
About Claris Lifesciences Ltd.
VISION
To be one of the worlds’ leading and most admired pharmaceutical companies in the global
Generics industry.
BUSINESSES
• Anesthesia
• Clinical Nutrition
• Oncology
• Anti infectives
• Infusion therapy
• Pharmaceutical Generics
MARKET PRESENCE:
• Presence in 76 countries across Latin America, Europe, Gulf, Africa, CIS, Central
Asia and Asia- Pacific
9
MANUFACTERING
• World class facilities designed to manufacture aqueous and lipid emulsion products
across various drug delivery systems.
• Bags
Multi-chamber bags
• Glass containers
Bottles
Vials
Ampoules
• Aseptic manufacturing
Liquid form
Oral Form
• Lyophilization
• Prefilled syringes
Glass
• Liposomal technology
Cytotoxic
• Blow-Fill-Seal.
10
Emotional Pharmacopoeia
The company's philosophy is based on Emotional Pharmacopoeia. A pharmacopoeia
is a document, which gives various guidelines about making a product. Different countries
like USA, UK, INDIA have their own pharmacopoeia. We have gone one step ahead and
made an emotional pharmacopoeia, which means every time you make, release or market a
product, the first question you should ask is “Can we use it on our dearest ones?” If your
heart says yes, with 100% confidence about its quality, you can accept the product and make
it available to save lives of patients across the world.
(Source: clarislifesciences.com)
11
RESEARCH DESIGN
This design consist of sample of Retailers in East zone of Ahmedabad, to understand the
movement of Injectable molecules.
12
Scheduling
The research is completed within the time span of eight weeks starting from 20th May .The
schedule is presented here week wise.
13
DATA ANALYSIS AND FINDING (BASED ON
POTENTIAL)
15
5 MOLECULES WITH HIGEST POTENTIAL
Molecules POTENTIAL(Rs.) % SHARE
Amoxicillin + Clavulanic Acid 220472.62 36 %
Pantoprazole 92967.00 15 %
Ondansetron 89129.48 14 %
Graph shows the relation between molecules and their potentials. Amoxicillin + Clavulanic
acid has the highest potential while other molecules follow it up.
16
Graph shows the percentage share of 5 Molecules having the highest potential. Amoxicillin +
Clavulanic acid has the highest percentage share while other molecules follow it up.
17
MOLECULES – AREA - TOTAL
Sr.No Molecules Name of Area Potential (Rs.)
1 Amoxicillin + Clavulanic Acid Meghani nagar 108811.67
Maninagar 68409.00
C.T.M 19327.95
Kankaria 16340.00
BAPUNAGAR 6004.00
VASTRAL 1580.00
Maninagar 40439.43
BAPUNAGAR 35877.50
Kankaria 8139.80
ODHAV 7367.50
C.T.M 4762.50
Amraiwadi 3492.50
VASTRAL 2984.50
Maninagar 34528.00
BAPUNAGAR 8656.55
Kankaria 6591.35
18
C.T.M 2234.35
ODHAV 1490.00
Amraiwadi 1421.75
BAPUNAGAR 24957.83
C.T.M 4765.00
Kankaria 3529.50
VASTRAL 1979.65
ODHAV 1642.50
Amraiwadi 1590.00
Maninagar 19578.43
BAPUNAGAR 5173.80
Amraiwadi 3544.98
Kankaria 3132.07
VASTRAL 1377.50
ODHAV 772.90
C.T.M 600.00
19
AREA – MOLECULES - POTENTIAL
Potential of Molecules in Bapunagar area.Amikacin Sulphate has the highest potential while
other molecules follow it up.
21
Potential of different molecules in C.T.M area.
Potential of Molecules in C.T.M area.Amoxicillin + Clavulanic acid has the highest potential
while other molecules follow it up.
22
Kankaria Amoxicillin + Clavulanic Acid 16340.00
Amikacin Sulphate 8139.80
Pantoprazole 6591.35
Ondansetron 3529.50
Multivitamin Infusion 3132.07
Diclofenac Sodium 2058.00
Amoxicillin 1700.00
Vitamin B-Complex 1041.25
Tramadol 847.50
Frusemide 753.00
Ranitidine 733.70
Ampicillin 250 mg + Cloxacillin 250 mg 595.00
Gentamicin 530.00
Dexamethasone 427.80
Metoclopramide 207.00
Atropin Sulphate 198.75
Potential of Molecules in Kankaria area. Amoxicillin + Clavulanic acid has the highest
potential while other molecules follow it up.
23
Potential of different molecules in Maninagar area.
24
Potential of different molecules in Meghani nagar area.
Metoclopramide 345.00
25
Potential of different molecules in Odhav area.
Potential of molecules in Odhav area. Amikacin Sulphate has the highest potential while
other molecules follow it up.
26
Potential of different molecules in Vastral area.
Potential of Molecules in Vastral area. Amikacin Sulphate has the highest potential while
other molecules follow it up.
27
MOLECULE – HOSPITALS - POTENTIALS
L.G.Hospital 71026.50
Doctor's House 19327.95
Amoxicillin+ Clavulanic
Doctor 13722.50
Acid
House,R'St
Kakdiya Hos 6004.00
Matruchhaya 1580.00
Hospital wise potential of Amoxicillin+Clavulanic Acid. Civil Hospital shows the highest
potential among all the hospitals.
28
Potential of Amikacin Sulphate in different Hospitals.
Hospital wise potential of Amikacin Sulphate. Civil Hospital shows the highest potential
among all the hospitals.
29
Potential of Pantoprazole in different Hospitals.
L.G.Hospital 35368.23
Hospital wise potential of Pantoprazole. Civil Hospital shows the highest potential among all
the hospitals.
30
Potential of Ondasetron in different Hospitals.
Hospital wise potential of Ondasetron. L.G. Hospital shows the highest potential among all
the hospitals.
31
MOLECULE HOSPITALS POTENTIAL (Rs.)
L.G.Hospital 23800.93
Civil Hos 19966.48
Kakdiya Hos 5173.80
Multivitamin Infusion
Doctor House,R'St 2454.55
Matruchhaya 1377.50
Dr.House ODHAV 772.90
Doctor's House 600.00
Hospital wise potential of Multivitamin Infusion. L.G.Hospital shows the highest potential
among all the hospitals.
32
Competitors’ Scenario
Augmentin GSK
Moxclav REXCEL
Mikacin ARISTO
2 Amikacin Sulphate
Mikastar DISCOVERY
MANKIND
Amicin BIOCHEMIST
Pan 40 ALKEM
Pantop ARISTO
33
4 Ondansetron Emeset CIPLA
Ondem ALKEM
Periset IPCA
Vomikind MANKIND
Zofar SUN
Stean STRONCH
Ontic CORONA
Eldervit ELDER
Vitcofol FDC
MVI USV
Multivitamin
5 Optinuron LUPIN
Infusion
Nurokind MANKIND
Nervic UNIMARCK
Nervizen UNIMARCK
34
Schemes for molecules in particular area and potential of
Molecules under that scheme :
Amoxicillin + 220472.62
Clavulanic Acid Total
35
2 Amikacin Sulphate Meghani nagar 1+1 5080.00
2+1 3337.50
3+1 3175.00
5+1 3810.00
10+4 11294.20
5+1 6821.20
5+1/2 635.00
22+11 3810.00
3+1 952.50
5+1/2 1270.00
5+1/2 1789.80
10+4 1587.50
11+10 1905.00
37
4 Ondansetron Maninagar 10+1 6620.00
5+1 2510.00
9+1 1255.00
4+1 113.25
5+1 1020.00
4+1 680.00
4+2 396.50
38
Ondansetron Total 89129.48
20+1 1346.40
25+1 435.25
20+1 2470.50
39
ANALYSIS AND FINDING (BASED ON VOLUME)
Ranitidine 5475.00
Vitamin B-Complex 4455.00
Ondansetron 3381.00
Amikacin Sulphate 2677.00
Gentamicin 1565.00
Ampicillin 250 mg + Cloxacillin 250 mg 1355.00
Dexamethasone 1012.00
Amoxicillin 945.00
Tramadol 830.00
Chloroquine Phosphate 574.00
Metoclopramide 505.00
Atropin Sulphate 427.00
Frusemide 353.00
Calcium Gluconate 350.00
Matoclopramide 182.00
Ampicillin 1 g + Salbactum 0.5 g 109.00
Artesunate 25.00
Daizapam 5.00
40
Graph shows the relationship between molecules and quantity sold per month. Ranitidine has
the highest quantity sold while Vitamin B-Complex, Diclofenac Sodium, Multivitamin
Infusion, Ondasetron and others follow it up respectively.
41
5 MOST MOVEBLE MOLECULES (In terms of Quantity
sold per month)
Ranitidine 5475.00
Ondansetron 3381.00
Graph shows the relationship between molecules and quantity sold per month. Ranitidine has
the highest quantity sold while Vitamin B-Complex, Diclofenac Sodium, Multivitamin
Infusion, Ondasetron follow it up respectively.
42
Percentage share of Molecules in terms of Quantity (Monthly). Ranitidine has the highest
percentage (In terms of Quantity) while Vitamin B-Complex, Diclofenac Sodium,
Multivitamin Infusion, Ondasetron and others follow it up respectively.
43
MOLECULES – AREA - QUANTITY
MOLECULE AREA QUANTITY (MONTHLY)
Maninagar 1535.00
Meghani nagar 1440.00
BAPUNAGAR 1430.00
Ranitidine
Amraiwadi 330.00
ODHAV 230.00
Kankaria 230.00
C.T.M 150.00
VASTRAL 130.00
Ranitidine Total 5475.00
44
Total quantity of Vitamin B-Complex in different areas.
ODHAV 190.00
Amraiwadi 110.00
VASTRAL 45.00
Diclofenac Sodium Total 4210.00
47
MOLECULE AREA QUANTITY (MONTHLY)
BAPUNAGAR 1245.00
Maninagar 885.00
Meghani nagar 760.00
Ondansetron
C.T.M 175.00
Kankaria 120.00
VASTRAL 81.00
ODHAV 65.00
Amraiwadi 50.00
Ondansetron Total 3381.00
L.G.Hospital 1695.00
Matruchhaya 130.00
49
Total quantities(monthly) sold of Vitamin B-Complex according to Hospitals.
L.G.Hospital 1540.00
Vitamin B-Complex
Kakdiya Hos 735.00
Matruchhaya 110.00
50
Total quantities (monthly) sold of Diclofenac Sodium according to Hospitals.
L.G.Hospital 1440.00
Diclofenac Sodium
Kakdiya Hos 825.00
Matruchhaya 45.00
51
Total quantities (monthly) sold of Multivitamin Infusion according to Hospitals.
L.G.Hospital 1450.00
Matruchhaya 100.00
52
MOLECULE HOSPITAL QUANTITY
L.G.Hospital 930.00
Matruchhaya 81.00
COMPETITORS’ SCENARIO
53
Sr. No. MOLECULES BRANDS COMPANIES
Aciloc CADILA
Rantac J.B.C
1 Ranitidine
Zantac Dr. REDDY
Ranitin TORRENT
Nerobion MERCK
Vitamin B-Complex Polybion MERCK
2
Vitneurin GSK
Dainapar TROIKAA
Diclonec LUPIN
Vovaran NOVARTIS
3 Diclofenac Sodium Dicloran J.B.C
Diclozecic TORRENT
Emeset CIPLA
Ondem ALKEM
Periset IPCA
Vomikind MANKIND
Zofar SUN
4 Ondansetron Stean STRONCH
Vomiset INDI PHARMA
Ontic CORONA
Emset CIPLA
Vitcofol FDC
MVI USV
Optinuron LUPIN
5 Multivitamin Infusion Nurokind MANKIND
Nervic UNIMARCK
Nervizen UNIMARCK
Eldervit ELDER
54
No Scheme 825.00
10+1 530.00
Maninagar
20+1 140.00
9+1 40.00
Maninagar Total 1535.00
No Scheme 1150.00
20+1 110.00
Meghani nagar
5+1/2 100.00
10+1/2 80.00
Meghani nagar Total 1440.00
No Scheme 1050.00
BAPUNAGAR
20+1 380.00
BAPUNAGAR Total 1430.00
No Scheme 245.00
Ranitidine
15+1 30.00
Amraiwadi
20+1 30.00
5+1 25.00
Amraiwadi Total 330.00
No Scheme 215.00
ODHAV
10+2 15.00
ODHAV Total 230.00
No Scheme 150.00
Kankaria 20+1 50.00
9+1 30.00
Kankaria Total 230.00
C.T.M No Scheme 150.00
C.T.M Total 150.00
10+1 70.00
VASTRAL
No Scheme 60.00
VASTRAL Total 130.00
Ranitidine Total 5475.00
55
No Scheme 1630.00
Meghani nagar 20+1 100.00
10+1/2 50.00
Meghani nagar Total 1780.00
No Scheme 750.00
Maninagar
20+1 535.00
Maninagar Total 1285.00
No Scheme 435.00
10+1 160.00
BAPUNAGAR
Vitamin B-Complex 20+2 120.00
20+1 20.00
BAPUNAGAR Total 735.00
No Scheme 165.00
Kankaria
20+1 80.00
Kankaria Total 245.00
Amraiwadi No Scheme 180.00
Amraiwadi Total 180.00
ODHAV No Scheme 120.00
ODHAV Total 120.00
VASTRAL No Scheme 110.00
VASTRAL Total 110.00
Vitamin B-Complex Total 4455.00
56
No Scheme 1275.00
10+1 130.00
Meghani nagar
Net 50.00
20+1 50.00
Meghani nagar Total 1505.00
Maninagar No Scheme 1135.00
5+1/2 100.00
10+1 90.00
Maninagar Total 1325.00
No Scheme 780.00
BAPUNAGAR
10+1 45.00
Diclofenac Sodium
BAPUNAGAR Total 825.00
No Scheme 140.00
Kankaria
10+1 70.00
Kankaria Total 210.00
No Scheme 125.00
ODHAV 9+1 55.00
10+1 10.00
ODHAV Total 190.00
No Scheme 60.00
Amraiwadi
20+2 50.00
Amraiwadi Total 110.00
VASTRAL No Scheme 45.00
VASTRAL Total 45.00
Diclofenac Sodium Total 4210.00
57
No Scheme 1400.00
20+1 120.00
Meghani nagar
10+1 50.00
25+1 50.00
Meghani nagar Total 1620.00
No Scheme 1015.00
Maninagar 20+1 150.00
10+1 20.00
Maninagar Total 1185.00
Multivitamin Infusion BAPUNAGAR No Scheme 460.00
BAPUNAGAR Total 460.00
Kankaria No Scheme 215.00
Kankaria Total 215.00
Amraiwadi No Scheme 210.00
Amraiwadi Total 210.00
VASTRAL No Scheme 100.00
VASTRAL Total 100.00
ODHAV No Scheme 90.00
ODHAV Total 90.00
C.T.M No Scheme 60.00
C.T.M Total 60.00
Multivitamin Infusion
Total 3940.00
58
No Scheme 1225.00
BAPUNAGAR
4+1 20.00
BAPUNAGAR Total 1245.00
No Scheme 485.00
10+1 250.00
Maninagar
5+1 100.00
9+1 50.00
Maninagar Total 885.00
No Scheme 730.00
Meghani nagar
9+1 30.00
Meghani nagar Total 760.00
No Scheme 140.00
C.T.M
5+1 35.00
Ondansetron
C.T.M Total 175.00
Kankaria No Scheme 120.00
Kankaria Total 120.00
5+1 30.00
10+4 25.00
VASTRAL
No Scheme 21.00
4+1 5.00
VASTRAL Total 81.00
ODHAV No Scheme 20.00
4+1 20.00
4+2 15.00
10+1 10.00
ODHAV Total 65.00
Amraiwadi No Scheme 50.00
Amraiwadi Total 50.00
Ondansetron Total 3381.00
59
ASSUMPTION
In this study it is assumed that the entire population of retailers selling different
injectable drugs is represented by the selected sample.
LIMITATION
Survey does not include the Hospital Pharmacy.
Quantity values are approximate and it does not indicate the actual number.
In particular area no. of medicals responded are less than the actual no. of medicals
present in area.
60
CONCLUSION
Conclusion form the sample surveyed to understand the movement of most movable
Injectable molecule ;
BASED ON POTENTIAL
From the Survey,
► Amoxicillin + Clavulanic Acid has the highest potentials, while Amikacin
Sulphate, Pantoprazole, Ondansetron, Multivitamin Infusion follow it up
respectively.
61
Graph shows the percentage share of 5 Molecules having the highest potential. Amoxicillin +
Clavulanic acid has the highest percentage share while other molecules follow it up.
62
BASED ON VOLUME (No. OF QUANTITY SOLD PER MONTH)
► Ranitidine has the highest no. of quantity sold per month while Vitamin B-Complex,
Diclofenac Sodium, Multivitamin Infusion, Ondansetron follow it up respectively.
63
Percentage share of Molecules in terms of Quantity(Monthly). Ranitidine has the highest
percentage (In terms of Quantity) while Vitamin B-Complex, Diclofenac Sodium,
Multivitamin Infusion, Ondasetron and others follow it up respectively.
64
RECOMMANDATION
From the Report and Analysis of Data, I would suggest five molecules with respect two
different view.
To gain the potential in new molecules, I would recommend the company to go with
the five molecules having the highest potential. They are ;
Amikacin Sulphate
Pantoprazole
Multivitamin Infusion
Ondasetron respectively.
To build up money rotation, I would suggest company to go with the molecules which
are sold in highest quantity per month. They are ;
Ranitidine
Vitamin B-Complex
Diclofenac sodium
Multivitamin Infusion
Ondasetron respectively.
65
BIBLIOGRAPHY
BOOKS
IDR
WEBSITES
www.clarislifesciences.com
www.evaluatepharma.com
www.pharmaceutical-technology.com
www.pharmafocusasia.com
www.worldpharmanews.com
economictimes.indiatimes.com
www.pharmainfo.com
www.pharmaworld.com
66
ANNEXURE
QUESTIONNAIRE
Name of Retailer: Date:
Area:
Qty Sold
S. No. Generic Name Strength Competitor Information
Per Week
Brand Name MRP Brand Name MRP Brand Name MRP Scheme
1 Amikacin Sulphate 50 mg/ml
2 Amikacin Sulphate 125 mg/ml
3 Amikacin Sulphate 250 mg/ml
4 Ampicillin 1 g + Salbactum 0.5 g
5 Amoxicillin 250 mg
6 Amoxicillin 500 mg
7 Amoxicillin + Clavulanic Acid
8 Ornidazole 5 mg/ml
9 Ampicillin 250 mg + Cloxacillin 250 mg
10 Ampicillin Sodium 500 mg
11 Meropenem
12 Gentamicin 10 mg/ml
12 Rabeprazole 20 mg
13 Ranitidine 25 mg/ml
14 Pantoprazole 40 mg/ml
15 Diclofenac Sodium 25 mg/ml
16 Ketorolac 30 mg/ml
17 Tramadol 50 mg/ml
18 Ondansetron 1 mg/ml
19 Metoclopramide 5 mg/ml
20 Dexamethasone 4 mg/ml
21 Hydrocortisone 100 mg/ml
22 Diazepam 10 mg/ml
23 Artemether 40 mg/ml
24 Artemether 80 mg/ml
25 Artesunate 60 mg/ml
26 Chloroquine Phosphate 64.5 mg
27 Frusemide 10 mg/ml
28 Multivitamin Infusion
29 Vitamin B-Complex
30 Calcium Gluconate 100 mg/ml
31 Atropine Sulphate 1 mg/ml
67